Optimizing Hidradenitis Suppurativa Management: From Current Challenges to Emerging Therapies and Future Perspectives | videos

Panelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.

Panelists discuss how managing patient expectations while implementing combination treatment approaches can optimize outcomes in hidradenitis suppurativa, emphasizing the importance of clear communication about treatment goals and timelines.

Panelists discuss how early recognition of hidradenitis suppurativa coupled with timely initiation of biologic therapies can significantly improve treatment outcomes and prevent disease progression.

Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.

Panelists discuss how artificial intelligence could revolutionize HS diagnosis through automated image analysis, pattern recognition of clinical presentations, and improved early detection capabilities, potentially reducing diagnostic delays.

Panelists discuss future innovations in hidradenitis suppurativa (HS) treatment and recommendations for guidelines and support groups.

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Panelists discuss how hidradenitis suppurativa significantly impacts patients' quality of life through chronic pain, skin lesions, and social stigma, while remaining frequently misdiagnosed or diagnosed late due to low disease awareness among healthcare providers.